The Rationale for Performance of Coronary Angiography and Stenting Before Transcatheter Aortic Valve Replacement From the Interventional Section Leadership Council of the American College of Cardiology Article

Full Text via DOI: 10.1016/j.jcin.2016.09.024 PMID: 27931592 Web of Science: 000392618900003

Cited authors

  • Ramee, Stephen; Anwaruddin, Saif; Kumar, Gautam; Piana, Robert N.; Babaliaros, Vasilis; Rab, Tanveer; Klein, Lloyd W.


  • Transcatheter aortic valve replacement (TAVR) is an effective, nonsurgical treatment option for patients with severe aortic stenosis. The optimal treatment strategy for treating concomitant coronary artery disease (CAD) has not been tested prospectively in a randomized clinical trial. Nevertheless, it is standard practice in the United States to perform coronary angiography and percutaneous coronary intervention for significant CAD at least 1 month before TAVR. All existing clinical trials were designed using this strategy. Therefore, it is wrong to extrapolate current American College of Cardiology/American Heart Association Appropriate Use Criteria against invasive procedures in asymptomatic patients to the TAVR population when evaluating the quality of care by cardiologists or hospitals. In this statement from the Interventional Section Leadership Council of the ACC, it is recommended that percutaneous coronary intervention should be considered in all patients with significant proximal coronary stenosis in major coronary arteries before TAVR, even though the indication is not covered in current guidelines. (J Am Coll Cardiol Intv 2016; 9: 2371-5) (C) 2016 by the American College of Cardiology Foundation.

Publication date

  • 2016

Published in

International Standard Serial Number (ISSN)

  • 1936-8798

Start page

  • 2371

End page

  • 2375


  • 9


  • 23